Hormonal
Resistance training alone significantly lowers ApoB48 levels (a marker for chylomicron particles and atherosclerosis risk) compared to no exercise, despite not significantly improving other lipid profiles like triglycerides or cholesterol in this specific protocol.
While resistance training might not drastically change your standard cholesterol numbers in 12 weeks, it does significantly improve specific blood markers (ApoB48) linked to heart disease risk. Incorporating weight training is a valuable tool for cardiovascular health, even if your standard lipid panel looks normal.
Levels of ApoB48 were 32% lower in the Resistance group compared to Control (p = 0.04).
Why this rating
RCT design, statistically significant result (p=0.04).
Source
The effect of 12 weeks of aerobic, resistance or combination exercise training on cardiovascular risk factors in the overweight and obese in a randomized trial
Suleen Ho et al. · BMC Public Health · 2012
DOI 10.1186/1471-2458-12-704
More from this paper
- Combination exercise (15 min aerobic + 15 min resistance, 5 days/week for 12 weeks) produces significantly greater reductions in body weight, total body fat, and android (abdominal) fat compared to resistance training alone or no exercise in overweight and obese adults.Good
- Combination exercise significantly improves cardio-respiratory fitness (VO2max) by 13.3% compared to no exercise, whereas aerobic or resistance training alone did not show statistically significant improvements in this specific 12-week moderate-intensity protocol.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →